Company intelligence / Profile preview

Global BioPharma

Ownership: Private
Development stage: Preclinical

Overview

GBS Global Biopharma has demonstrated statistically significant animal proof-of-concept results in Parkinson’s disease models and positive preclinical data for COVID-related cytokine release syndrome. The company holds several issued U.S. patents on its proprietary cannabinoid-containing formulations targeting multiple indications. Human clinical trials are planned but have not yet commenced as of the latest updates.[1]

Therapeutic areas: OtherCardiovascularNeurologyInfectious Diseases
Modalities: Plant-based mixtures (including cannabinoids)Minimum essential mixtures of plant-inspired compounds[1]
Industry: Biotech

Partnerships

Research partnerships with nine international universities over seven years.Development partners providing cGMP-certified active ingredients and oral delivery expertise.[1]

Beyond the preview

Go deeper on Global BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Global BioPharma.

Explore the full profile